Manzamine A

Research use only, not for human use.

Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC50s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1.

Manzamine A is a GSK-3 inhibitor and vacuolar ATPase uncoupler found in marine sponges.

Manzamine A (5-50 μM, 18 h) decreases tau phosphorylation, measured with ELISA.Manzamine A (10 μM) inhibits yeast S. cerevisiae growth by 30%.Manzamine A displays a few enlarged vacuoles in yeast.Manzamine A (2.5-10 μM, 24 h) increases acidity in pancreatic cancer cells and non-malignant Vero cells.Manzamine A (1 μM, 24 h) inhibits HSV-1 infection in SIRC cells.Manzamine A shows antimalarial activity with an IC50 of 8.0 nM (D6 clone) and 11 nM (W2 clone).Cell Viability Assay Cell Line:SIRC cell Concentration:0.1, 0.5, 1, 2, 3, 5, and 10 μMv Incubation ime:72 hvResult:Inhibited SIRC cell viability with an IC50 of 5.6 μM.

Manzamine A (50 and 100 mol/kg, p.o. or i.p.) inhibits the growth of the rodent malaria parasite Plasmodium berghei in infected mice.Manzamine A (8 mg/kg, i.p., daily for 8 consecutive days) prolongs the survival of SW mice to 20 days.Animal Model:Plasmodium berghei in infected mice Dosage:50 or 100 mol/kg Administration:Intraperitoneal injection (i.p.) or oral administration (p.o.) Result:Inhibited the growth of the rodent malaria parasite Plasmodium berghei.Prolonged the survival of highly parasitaemic mice.

———

Others

Other Targets

———

———

———

104196-68-1

548.775

C36H44N4O

>98% (HPLC)

DMSO : 10 mg/mL (18.22 mM; ultraphonic; )

———

——

(-20℃)

With Ice Pack

≥ 2 years